Literature DB >> 16261595

Inherited predispositions and hyperactive Ras in myeloid leukemogenesis.

Jennifer O Lauchle1, Benjamin S Braun, Mignon L Loh, Kevin Shannon.   

Abstract

Identifying the molecular basis for inherited cancer predispositions reveals genes that when mutated, play a critical role in the earliest stages of tumorigenesis. Although rare, inherited predispositions to myeloid leukemias have led to a greater understanding of pathways important for myeloid proliferation and maturation. In particular, elucidating why children with neurofibromatosis type 1 (NF1) and Noonan syndrome (NS) are predisposed to juvenile myelomonocytic leukemia (JMML) has uncovered a critical role of hyperactive Ras signaling in normal myeloid growth and leukemogenesis. Here, we review studies of human samples and experiments performed in genetically engineered strains of mice investigating the molecular and biochemical basis of aberrant growth in JMML. These strains model human disease features and provide an opportunity to investigate novel therapeutic strategies that may ultimately cure JMML and other myeloid malignancies characterized by hyperactive Ras.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16261595     DOI: 10.1002/pbc.20644

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  33 in total

Review 1.  Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras.

Authors:  Anica Wandler; Kevin Shannon
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

Review 2.  Therapy-related myeloid neoplasms: pathobiology and clinical characteristics.

Authors:  H Sill; W Olipitz; A Zebisch; E Schulz; A Wölfler
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

3.  Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo.

Authors:  Benjamin S Braun; Joehleen A Archard; Jessica A G Van Ziffle; David A Tuveson; Tyler E Jacks; Kevin Shannon
Journal:  Blood       Date:  2006-05-23       Impact factor: 22.113

4.  Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL.

Authors:  Yuan Ren; Zhengming Chen; Liwei Chen; Nicholas T Woods; Gary W Reuther; Jin Q Cheng; Hong-gang Wang; Jie Wu
Journal:  J Biol Chem       Date:  2007-10-17       Impact factor: 5.157

Review 5.  GAB2--a scaffolding protein in cancer.

Authors:  Sarah J Adams; Iraz T Aydin; Julide T Celebi
Journal:  Mol Cancer Res       Date:  2012-08-07       Impact factor: 5.852

6.  High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

Authors:  Jeffrey W Tyner; Heidi Erickson; Michael W N Deininger; Stephanie G Willis; Christopher A Eide; Ross L Levine; Michael C Heinrich; Norbert Gattermann; D Gary Gilliland; Brian J Druker; Marc M Loriaux
Journal:  Blood       Date:  2008-12-15       Impact factor: 22.113

7.  Biochemical and functional characterization of germ line KRAS mutations.

Authors:  Suzanne Schubbert; Gideon Bollag; Natalya Lyubynska; Hoa Nguyen; Christian P Kratz; Martin Zenker; Charlotte M Niemeyer; Anders Molven; Kevin Shannon
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

8.  Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.

Authors:  Hideki Muramatsu; Hideki Makishima; Anna M Jankowska; Heather Cazzolli; Christine O'Keefe; Nao Yoshida; Yinyan Xu; Nobuhiro Nishio; Asahito Hama; Hiroshi Yagasaki; Yoshiyuki Takahashi; Koji Kato; Atsushi Manabe; Seiji Kojima; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

9.  Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1.

Authors:  Doris Steinemann; Larissa Arning; Inka Praulich; Manfred Stuhrmann; Henrik Hasle; Jan Stary; Brigitte Schlegelberger; Charlotte M Niemeyer; Christian Flotho
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

10.  K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.

Authors:  Thomas Kindler; Melanie G Cornejo; Claudia Scholl; Jianing Liu; Dena S Leeman; J Erika Haydu; Stefan Fröhling; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2008-07-28       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.